Registration Document

Overview

The report describes Onxeo's 2016 acquisition of DNA Therapeutics and the resulting development of the AsiDNA oncology program. Consolidated revenue increased to €4,423,000 from €3,481,000 in 2015, driven largely by licensed-partner sales and royalties. The report also presents extensive social, environmental and societal information, including workforce, health and safety, training, pollution and waste management. An independent verifier provided limited assurance over the consolidated CSR information and reasonable assurance over selected information.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2016
Period: 1 January 2016 – 31 December 2016
Publication date: 24 April 2017
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services